Drug details
Brukinsa (zanubrutinib capsules)
type of Antineoplastic Tyrosine Kinase Inhibitors
Brukinsa (zanubrutinib) is a kinase inhibitor used to treat adult patients with mantle cell lymphoma (MCL) who have received at least one prior therapy.
This drug may have the following side effects:
- hives,
- difficulty breathing,
- swelling of your face, lips, tongue, or throat,
- loss of appetite,
- vomiting,
- fever,
- easy bruising,
- unusual bleeding,
- pale skin,
- lightheadedness,
- shortness of breath,
- cold hands and feet,
- chills,
- vision problems,
- fluttering in your chest,
- severe headache,
- weakness,
- cough,
- unusual tiredness,
- sore throat,
- fast or irregular heartbeat,
- mouth sores,
- right-sided upper stomach pain,
- pounding heartbeats,
- bloody or tarry stools,
- coughing up blood,
- vomit that looks like coffee grounds,
- skin sores,
- feeling unwell,
- chest discomfort,
- purple or red spots under your skin,
- yellowing of your skin or eyes,
- red or pink urine,
- trouble speaking or understanding what is said to you,
- numbness or weakness on one side,
- redness or swelling, and
- cough with mucus
The following drugs are related to Brukinsa, either as a replacement or used together:
- Calquence (acalabrutinib capsules)
- Arzerra (ofatumumab injection)
- Tecartus (brexucabtagene autoleucel suspension)
- Breyanzi (lisocabtagene maraleucel suspension for intravenous infusion)
- Columvi (glofitamab-gxbm injection)
- Imbruvica (ibrutinib capsules)
- Revlimid (lenalidomide)
- Zynlonta (loncastuximab tesirine-lpyl for injection)
- Riabni (rituximab-arrx injection)
- Torisel (temsirolimus injection)
- Ukoniq (umbralisib tablets)
- Venclexta (venetoclax tablets)